Is Lakefront Biotherapeutics N.V. (LKFT) a Buy, Sell, or Hold?
Lakefront Biotherapeutics N.V.
NASDAQ:LKFT
$29.48 USD
$0.01 (0.03%)
- Volume
- 80.84K
- Average Volume
- 164.51K
- Market Capitalization
- $1.94B
- P/E Ratio
- 3.46
- Dividend Yield
- 0.00%
- Price Target
- $30.00
- Year High
- $37.78
- Year Low
- $26.42
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $30.48
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Henry O. Gosebruch |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | LKFT |
| CUSIP | 36315X101 |
| CIK | 0001421876 |
| Web | https://lakefrontbio.com |
| Phone | 32 1 534 29 00 |
| Currency | USD |
| Employees | 452 |
| Country | BE |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 30.48 |
| Quick Ratio | 30.30 |
| Cash Ratio | 0.67 |
Sales & Book Value
| Annual Sales | $1.11B |
| Price / Sales | 1.62 |
| Cash Flow | -4.71 |
| Price / Cash Flow | -5.46 |
| Price / Book | 0.52 |
Price Target and Rating
| Average Stock Price Forecast | $30.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $30.00 |
| Forecast Upside/Downside | -1.73% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $4.87 |
| Trailing P/E Ratio | 3.46 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $320.88M |
| Net Margin | 46.83% |
| Pretax Margin | 45.14% |
| Return on Equity | 16.88% |
| Return on Assets | 14.49% |
Financials Score
| AltmanZ Score | |
| Piotroski Score | |
| Working Capital | - |
| Total Assets | - |
| Ebit | - |
| Market Cap | - |
| Total Liabilities | - |
Poll Results
About Lakefront Biotherapeutics N.V. (NASDAQ:LKFT) Stock
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium. ...
2026-07-14 16:01:00
Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 108,645 Lakefront shares between 06 July 2026 and 10 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 06/07/2026 XAMS 20,236 26.54 536,964.28 26.20 26.90 06/07/2026 CEUX 2,499 26.69 66,710.06 26.32 26.90 06/07/2026 TQEX 355 26.72 9,486.20 26.52 26.90 06/07/2026 AQEU 319 26.58 8,477.65 26.52 26.88 07/07/2026 XAMS 16,553 26.65 441,104.34 26.40 26.86 07/07/2026 CEUX 1,578 26.55 41,894.01 26.44 26.76 07/07/2026 TQEX 821 26.64 21,872.92 26.60 26.70 07/07/2026 AQEU 49 26.60 1,303.40 26.60 26.60 08/07/2026 XAMS 17,502 26.84 469,793.93 26.66 27.00 08/07/2026 CEUX 4,339 26.89 116,674.84 26.74 26.96 08/07/2026 TQEX 1,157 26.87 31,086.62 26.76 26.94 08/07/2026 AQEU 416 26.86 11,172.18 26.80 26.94 09/07/2026 XAMS 16,919 26.77 452,892.87 26.56 26.90 09/07/2026 CEUX 2,717 26.79 72,781.09 26.70 26.96 09/07/2026 TQEX 23 26.76 615.48 26.76 26.76 09/07/2026 AQEU 400 26.77 10,707.04 26.76 26.78 10/07/2026 XAMS 19,764 26.52 524,208.48 26.14 26.90 10/07/2026 CEUX 2,009 26.66 53,568.98 26.26 26.92 10/07/2026 TQEX 692 26.65 18,443.74 26.24 26.78 10/07/2026 AQEU 297 26.82 7,964.53 26.26 26.92 Total 108,645 26.67 2,897,722.65 26.14 27.00 As of market close on 10 July 2026, Lakefront holds 412,401 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
2026-07-13 16:01:00
Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research and Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.
2026-07-13 16:01:00
Mechelen, België; 13 juli 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) heeft vandaag bekendgemaakt dat dr. Paulo Fontoura, na zijn benoeming tot Executive Vice President en Global Head of Research and Development Pharma bij Sanofi SA, zijn mandaat als lid van de Raad van Bestuur heeft neergelegd. "Ik wil Paulo feliciteren met deze belangrijke benoeming en hem oprecht bedanken voor zijn inzichten en begeleiding tijdens zijn ambtstermijn in onze Raad van Bestuur.
2026-07-13 16:01:00
Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.
2026-07-07 16:01:00
Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 104,022 Lakefront shares between 29 June 2026 and 03 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 29/06/2026 XAMS 14,414 25.75 371,205.18 25.60 26.00 29/06/2026 CEUX 3,399 25.74 87,478.36 25.66 26.00 29/06/2026 TQEX 696 25.71 17,897.29 25.66 26.00 29/06/2026 AQEU 916 25.71 23,551.83 25.66 25.80 30/06/2026 XAMS 19,724 26.37 520,179.08 25.98 26.74 30/06/2026 CEUX 2,068 26.45 54,694.67 26.22 26.72 30/06/2026 TQEX 508 26.53 13,478.15 26.14 26.78 30/06/2026 AQEU 445 26.09 11,610.94 26.08 26.12 01/07/2026 XAMS 20,787 26.30 546,681.47 26.06 26.48 01/07/2026 CEUX 2,613 26.20 68,467.39 26.12 26.44 01/07/2026 TQEX 71 26.40 1,874.32 26.32 26.40 01/07/2026 AQEU 198 26.17 5,181.78 26.16 26.30 02/07/2026 XAMS 13,778 26.14 360,180.34 25.88 26.54 02/07/2026 CEUX 3,021 26.06 78,727.86 25.96 26.12 02/07/2026 TQEX 115 26.23 3,015.94 25.96 26.46 02/07/2026 AQEU 721 26.12 18,835.04 25.96 26.14 03/07/2026 XAMS 15,162 26.62 403,642.76 26.46 26.86 03/07/2026 CEUX 4,786 26.59 127,266.92 26.50 26.86 03/07/2026 TQEX 526 26.75 14,071.18 26.50 26.88 03/07/2026 AQEU 74 26.62 1,970.16 26.52 26.64 Total 104,022 26.24 2,730,010.70 25.60 26.88 As of market close on 03 July 2026, Lakefront holds 303,756 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
2026-06-30 16:01:00
Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 83,530 Lakefront shares between 22 June 2026 and 26 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 22/06/2026 XAMS 15,297 24.59 376,162.41 24.38 24.96 23/06/2026 XAMS 15,050 25.32 381,076.53 25.06 25.52 24/06/2026 XAMS 18,944 25.55 483,992.68 25.30 25.78 25/06/2026 XAMS 17,239 25.41 438,065.40 25.12 25.72 26/06/2026 XAMS 17,000 25.22 428,748.50 24.94 25.82 Total 83,530 25.24 2,108,045.52 24.38 25.82 As of market close on 26 June 2026, Lakefront holds 199,734 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Lakefront Receives Transparency Notification from Madison Avenue Partners
2026-06-29 16:01:00
Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.
2026-06-23 16:01:00
Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 77,667 Lakefront shares between 15 June 2026 and 19 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 15/06/2026 EXNT 13,272 24.9331 330,912.10 24.7200 25.2200 16/06/2026 EXNT 16,400 24.5495 402,611.80 24.1200 25.2600 17/06/2026 EXNT 13,605 24.4212 332,250.43 24.0000 24.7800 18/06/2026 EXNT 16,960 24.8036 420,669.06 24.4800 25.1200 19/06/2026 EXNT 17,430 24.5966 428,718.74 24.3600 24.7600 Total 77,667 24.6586 1,915,162.13 24.3360 25.0280 As of market close on 19 June 2026, Lakefront holds 116,204 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
Frequently Asked Questions
-
What is the current Lakefront Biotherapeutics N.V. (LKFT) stock price?
-
Lakefront Biotherapeutics N.V.(NASDAQ:LKFT) stock price is $29.48 in the last trading session. During the trading session, LKFT stock reached the peak price of $37.78 while $26.42 was the lowest point it dropped to. The percentage change in LKFT stock occurred in the recent session was 0.03% while the dollar amount for the price change in LKFT stock was $0.01.
-
LKFT's industry and sector of operation?
-
The NASDAQ listed LKFT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LKFT?
-
Jeevan Shetty | Head of Clinical Development Oncology
John W. Mellors | Head of Cell & Antibody Therapy Discovery
Fred W. Blakeslee | Executive VP & General Counsel
Henry Gosebruch | CEO & Executive Director
Annelies Missotten | Executive Officer -
How many employees does LKFT have?
-
Number of LKFT employees currently stands at 452. LKFT operates from SchaliEnhoevedreef 20 T, Mechelen, None 2800, BE.
-
Link for LKFT official website?
-
Official Website of LKFT is: https://lakefrontbio.com
-
How do I contact LKFT?
-
LKFT could be contacted at phone #32 1 534 29 00 and can also be accessed through its website. LKFT operates from SchaliEnhoevedreef 20 T, Mechelen, None 2800, BE.
-
How many shares of LKFT are traded daily?
-
The average number of LKFT shares traded daily for last 3 months was 164.51K.
-
What is the market cap of LKFT currently?
-
The market value of LKFT currently stands at $1.94B with its latest stock price at $29.48